This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

New Published Clinical Study Shows Masimo PVI® Helps Clinicians Assess Fluid Responsiveness In Pediatric Patients

Stocks in this article: MASI

IRVINE, Calif., May 15, 2013 /PRNewswire/ --  Masimo (NASDAQ: MASI) announced today a new study in the British Journal of Anesthesia demonstrates that Masimo's noninvasive PVI ® can be used to help clinicians accurately assess fluid responsiveness in mechanically ventilated children under general anesthesia, 1 adding to the growing body of evidence that shows the efficacy of PVI across a wide range of patient populations.

Hemodynamic instability is a common challenge in surgical and critically ill patients. When necessary, fluid administration is critical to optimizing patient status and enabling end organ preservation, 2 but unnecessary fluid administration is associated with increased morbidity and mortality. 3 The decision whether to administer fluid in an attempt to improve cardiac output can be challenging because traditional invasive methods can be inaccurate at predicting fluid responsiveness while newer dynamic indicators for assessing fluid responsiveness are accurate but are either invasive, operator-dependent, or costly. 4,5

In the study conducted at Seoul National University Hospital in Seoul, South Korea, researchers evaluated 33 pediatric patients undergoing neurosurgery, ranging in age from 6 months to 9 years. Investigators evaluated measurements from commonly used invasive and complex techniques including: central venous pressure (CVP), systolic pressure variation (SPV), pulse pressure variation (PPV), change in inferior vena cava diameter measurement (∆IVCD), and respiratory aortic blood flow velocity (ΔV peak), while also evaluating Masimo's noninvasive and automated PVI (Masimo Radical-7 ®). All measurements were compared before volume expansion and whether their values were associated with a significant change in stroke volume index (SVI). There were 15 volume responders (≥10% increase in SVI after volume expansion) and 18 non-responders (<10% increase in SVI after volume expansion). Researchers found that only PVI >11% (with sensitivity of 73.3% and specificity of 86.7%) and ΔV peak of >11% (with sensitivity of 86.7% and specificity of 72.2%) predicted fluid responsiveness. All other measures (CVP, SPV, PPV, ∆IVCD) were not associated with an improvement in SVI and therefore were poor predictors of fluid responsiveness.

The researchers noted that while both ΔV peak and PVI are noninvasive and have been shown to be good indicators of fluid responsiveness in various clinical settings, ΔV peak is dependent on a skilled operator with costly imaging equipment, while PVI can be used by clinicians who can use a pulse oximeter.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs